Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | DKK1 | O94907 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906911 | 0.84 | IKBKB (0.42) | TRHDEMAPK1CYP11B1CYP11B2TNIK | |
| SCHEMBL4904630 | 0.83 | DKK1 (0.36) | TRHDEMAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL4906253 | 0.83 | DKK1 (0.36) | TRHDEMAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL4902912 | 0.83 | DKK1 (0.39) | TRHDEMAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL4896119 | 0.82 | MAPK1 (0.37) | TRHDEMAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL4904628 | 0.82 | MAPK1 (0.35) | MAPK1CCNA2CDK2MAPK3DKK1 | |
| SCHEMBL4900193 | 0.81 | DKK1 (0.36) | TRHDEMAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL4907640 | 0.78 | ALDH1A1 (0.39) | TRHDEMAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL4899730 | 0.77 | MEN1 (0.44) | MAPK1CDK2DKK1GSK3BDYRK1B | |
| SCHEMBL4904704 | 0.76 | MAPK1 (0.41) | MAPK1CCNA2CDK2MAPK3DKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT3A, CTNNB1, WNT1 | TRHDE 4523/4885MAPK1 1144/4885CCNA2 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.